Table 3.
Univariate analyses for overall survival and progression‐free survival of the 40 patients with diffuse large B‐cell lymphoma treated with RCHOP
| 5 year OS (95% CI) | P | 5 year PFS (95% CI) | P | ||
|---|---|---|---|---|---|
| ECOG | ≤1 | 67% (47%, 87%) | 0.658 | 67% (47%, 87%) | 0.488 |
| >1 | 63% (41%, 85%) | 52% (29%, 75%) | |||
| Ann‐Arbor stage | I‐II | 91% (74%, 100%) | 0.091 | 91% (74%, 100%) | 0.064 |
| III‐IV | 55% (37%, 73%) | 48% (30%, 66%) | |||
| Serum LDH | Normal | 77% (57%, 97%) | 0.331 | 66% (44%, 88%) | 0.452 |
| High | 55% (34%, 76%) | 55% (34%, 76%) | |||
| N extranodal sites | ≤1 | 66% (49%, 83%) | 0.582 | 63% (46%, 80%) | 0.570 |
| >1 | 60% (30%, 90%) | 50% (19%, 81%) | |||
| Bone marrow involvement | No | 63% (47%, 79%) | 0.999 | 63% (47%, 79%) | 0.505 |
| Yes | 80% (45%, 100%) | 40% (0, 83%) | |||
| IPI score | 0–2 | 69% (50%, 88%) | 0.420 | 65% (45%, 85%) | 0.518 |
| 3–5 | 59% (36%, 82%) | 53% (29%, 77%) | |||
| CD4 | ≤200 | 69% (50%, 88%) | 0.284 | 69% (50%, 88%) | 0.157 |
| >200 | 63% (39%, 87%) | 50% (25%, 75%) | |||
| CD4 | ≤100 | 58% (34%, 82%) | 0.636 | 58% (34%, 82%) | 0.839 |
| >100 | 73% (54%, 92%) | 64% (44%, 84%) | |||
| HIV‐load | Non‐detectable | 86% (60%, 100%) | 0.261 | 62% (27%, 97%) | 0.478 |
| Detectable | 61% (43%, 79%) | 61% (43%, 79%) | |||
| cART before lymphoma | No | 71% (49%, 93%) | 0.276 | 71% (49%, 93%) | 0.201 |
| Yes | 59% (38%, 80%) | 50% (29%, 71%) | |||
| EBERs | Negative | 67% (50%, 84%) | 0.596 | 61% (44%, 78%) | 0.746 |
| Positive | 56% (23%, 89%) | 56% (23%, 89%) | |||
| CD30 expression | Negative | 71% (43%, 99%) | 0.791 | 58% (41%, 75%) | 0.965 |
| Positive | 69% (44%, 94%) | 67% (36%, 98%) | |||
| MYC expression | No | 70% (53%, 86%) | 0.153 | 70% (53%, 86%) | 0.055 |
| Yes | 50% (19%, 81%) | 30% (2%, 58%) | |||
| Double expresser status | No | 68% (53%, 83%) | 0.043 | 68% (53%, 83%) | 0.005 |
| Yes* | 40% (0, 83%) | 0 | |||
| COO subtype | GC | 79% (57%, 100%) | 0.082 | 79 (57%, 100%) | 0.061 |
| Non‐GC | 57% (38%, 76%) | 50 (30%, 69%) | |||
| MYC rearrangement | No | 65% (49%, 81%) | 0.656 | 62% (46%, 78%) | 0.716 |
| Yes | 67% (29%, 100%) | 50% (10%, 90%) | |||
| BCL6 rearrangement | No | 74% (58%, 91%) | 0.060 | 67% (49%, 84%) | 0.092 |
| Yes | 45% (17%, 72%) | 45% (17%, 72%) | |||
BL, Burkitt lymphoma; cART, combination antiretroviral therapy; COO, cell of origin; DLBCL, diffuse large B‐cell lymphoma; EBER, Epstein–Barr virus–encoded small RNAs; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic index; LDH, lactate dehydrogenase.